The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects.
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma.
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine."
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities.